Phase 1, Open-label, Single-dose Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Apr 2016
At a glance
- Drugs Guselkumab (Primary)
- Indications Erythrodermic psoriasis; Palmoplantar pustulosis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 11 Apr 2016 Status changed from recruiting to completed.
- 28 Oct 2015 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.
- 10 Oct 2015 New trial record